Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases

Current Opinion in Pharmacology

Volumn 3, Issue 4, 2003, Pages 396-403

  O'Neill, Luke A J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (5 METHYL 5 MORPHOLINOCARBONYL 1,3 DIOXAN 2 YL) 5 (4 PYRIDINYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ACETYLSALICYLIC ACID; ADAPTOR PROTEIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PARTHENOLIDE; PHOSPHOTRANSFERASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALICYLIC ACID; SPC 0023579; SYNAPTOPHYSIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ASTHMA; BACTERIAL INFECTION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE TARGETING; HOST RESISTANCE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; MIOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION;

ANIMALS; COMMUNICABLE DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; MEMBRANE GLYCOPROTEINS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE I; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 0042493163     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00080-8     Document Type: Review

References (52)

1. Sims J.E. March C.J. Cosman D. Widmer M.B. MacDonald H.R. McMahan C.J. Grubin C.E. Wignall J.M. Jackson J.L. Call S.M. et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily Science 241 1988 585-589
2. Gay N.J. Keith F. Drosophila Toll and IL-1 receptor Nature 351 1991 355-356
3. Lemaitre B. Nicolas E. Michaut L. Reichhart J.M. Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults Cell 86 1996 973-983
4. Medzhitov R. Preston-Hurlburt P. Janeway C.A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity Nature 388 1997 394-397
5. Rock F.L. Hardiman G. Timans J.C. Kastelein R.A. Bazan J.F. A family of human receptors structurally related to Drosophila Toll Proc. Natl. Acad. Sci. U.S.A. 95 1998 588-593
6. Poltorak A. He X. Smirnova I. Liu M.Y. Van Huffel C. Du X. Birdwell D. Alejos E. Silva M. Galanos C. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr-4 gene Science 282 1998 2085-2088
7. Hoshino K. Takeuchi O. Kawai T. Sanjo H. Ogawa T. Takeda Y. Takeda K. Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product J. Immunol. 162 1999 3749-3752
8. Qureshi S.T. Lariviere L. Leveque G. Clermont S. Moore K.J. Gros P. Malo D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4) J. Exp. Med. 189 1999 615-625
9. Dunne A. O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense Sci. STKE 171 2003 RE3
10. Wesche H. Henzel W.J. Shillinglaw W. Li S. Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex Immunity 7 1997 837-847
11. Medzhitov R. Preston-Hurlburt P. Kopp E. Stadlen A. Chen C. Ghosh S. Janeway C.A. Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways Mol. Cell 2 1998 253-258
12. Burns K. Martinon F. Esslinger C. Pahl H. Schneider P. Bodmer J.L. Di Marco F. French L. Tschopp J. MyD88, an adapter protein involved in interleukin-1 signaling J. Biol. Chem. 273 1998 12203-12209
13. Fitzgerald K.A. Palsson-McDermott E.M. Bowie A.G. Jefferies C.A. Mansell A.S. Brady G. Brint E. Dunne A. Gray P. Harte M.T. et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction Nature 413 2001 78-83
14. Horng T. Barton G.M. Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway Nat. Immunol. 2 2001 835-841
15. Horng T. Barton G.M. Flavell R.A. Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors Nature 420 2002 329-333
16. Yamamoto M. Sato S. Hemmi H. Sanjo H. Uematsu S. Kaisho T. Hoshino K. Takeuchi O. Kobayashi M. Fujita T. et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4 Nature 420 2002 324-329
17. Yamamoto M. Sato S. Mori K. Hoshino K. Takeuchi O. Takeda K. Akira S. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling J. Immunol. 169 2002 6668-6672
18. Oshiumi H.Matsumoto M.Funami K.Akazawa T.Seya T.TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction Nat. Immunol. 4 2003 161-167
19. O'Neill LAJ, Fitzgerald KA, Bowie AG: The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 2003, in press [doi:10.1016/S1471-4906(03)00115-7].
20. Persing D.H. Coler R.N. Lacy M.J. Johnson D.A. Baldridge J.R. Hershberg R.M. Reed S.G. Taking toll: lipid A mimetics as adjuvants and immunomodulators Trends Microbiol. 10Suppl. 2002 S32-S37
21. Ohashi K. Burkart V. Flohe S. Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex J. Immunol. 164 2000 558-561
22. Okamura Y. Watari M. Jerud E.S. Young D.W. Ishizaka S.T. Rose J. Chow J.C. Strauss J.F. III The extra domain A of fibronectin activates Toll-like receptor 4 J. Biol. Chem. 276 2001 10229-10233
23. Lorenz E. Mira J.P. Frees K.L. Schwartz D.A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock Arch. Intern. Med. 162 2002 1028-1032
24. Kiechl S. Lorenz E. Reindl M. Wiedermann C.J. Oberhollenzer F. Bonora E. Willeit J. Schwartz D.A. Toll-like receptor 4 polymorphisms and atherogenesis N. Engl. J. Med. 347 2002 185-192
25. Frantz S. Kobzik L. Kim Y.D. Fukazawa R. Medzhitov R. Lee R.T. Kelly R.A. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium J. Clin. Invest. 104 1999 271-280
26. Alexopoulou L. Holt A.C. Medzhitov R. Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 Nature 413 2001 732-738
27. Hemmi H. Kaisho T. Takeuchi O. Sato S. Sanjo H. Hoshino K. Horiuchi T. Tomizawa H. Takeda K. Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat. Immunol. 3 2002 196-200
28. Jurk M. Heil F. Vollmer J. Schetter C. Krieg A.M. Wagner H. Lipford G. Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 Nat. Immunol. 3 2002 499
29. Syed T.A. A review of the applications of imiquimod: a novel immune response modifier Expert Opin. Pharmacother. 2 2001 877-882
30. Takeuchi O. Sato S. Horiuchi T. Hoshino K. Takeda K. Dong Z. Modlin R.L. Akira S. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins J. Immunol. 169 2002 10-14
31. Takeuchi O. Kawai T. Muhlradt P.F. Morr M. Radolf J.D. Zychlinsky A. Takeda K. Akira S. Discrimination of bacterial lipoproteins by Toll-like receptor 6 Int. Immunol. 13 2001 933-940
32. Bowie A. Kiss-Toth E. Symons J.A. Smith G.L. Dower S.K. O'Neill L.A. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling Proc. Natl. Acad. Sci. U.S.A. 97 2000 10162-10167
33. Harte M.T. Haga I.R. Maloney G. Gray P. Reading P.C. Bartlett N.W. Smith G.L. Bowie A. O'Neill L.A. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense J. Exp. Med. 197 2003 343-351
34. Leadbetter E.A. Rifkin I.R. Hohlbaum A.M. Beaudette B.C. Shlomchik M.J. Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors Nature 416 2002 603-607
35. Lazarus R. Klimecki W.T. Raby B.A. Vercelli D. Palmer L.J. Kwiatkowski D.J. Silverman E.K. Martinez F. Weiss S.T. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three US ethnic groups and exploratory case-control disease association studies Genomics 81 2003 85-91
36. Suzuki N. Suzuki S. Duncan G.S. Millar D.G. Wada T. Mirtsos C. Takada H. Wakeham A. Itie A. Li S. et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4 Nature 416 2002 750-756
37. Ye H. Arron J.R. Lamothe B. Cirilli M. Kobayashi T. Shevde N.K. Segal D. Dzivenu O.K. Vologodskaia M. Yim M. et al. Distinct molecular mechanism for initiating TRAF6 signalling Nature 418 2002 443-447
38. Wang C. Deng L. Hong M. Akkaraju G.R. Inoue J. Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK Nature 412 2001 346-351
39. Epinat J.C. Gilmore T.D. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway Oncogene 18 1999 6896-6909
40. Haefner B. NF-κB: arresting a major culprit in cancer Drug Discov. Today 7 2002 653-663
41. Kopp E. Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin Science 265 1994 956-959
42. Almawi W.Y. Melemedjian O.K. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids J. Mol. Endocrinol. 28 2002 69-78
43. Kwok B.H. Koh B. Ndubuisi M.I. Elofsson M. Crews C.M. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase Chem. Biol. 8 2001 759-766
44. O'Neill L.A. Barrett M.L. Lewis G.P. Extracts of feverfew inhibit mitogen-induced human peripheral blood mononuclear cell proliferation and cytokine mediated responses: a cytotoxic effect Br. J. Clin. Pharmacol. 23 1987 81-83
45. Boehm J.C. Adams J.L. New inhibitors of p38 kinase Expert Opin. Ther. Pat. 10 2000 25-37
46. English J.M. Cobb M.H. Pharmacological inhibitors of MAPK pathways Trends Pharmacol. Sci. 23 2002 40-45
47. Kobayashi K. Inohara N. Hernandez L.D. Galan J.E. Nunez G. Janeway C.A. Medzhitov R. Flavell R.A. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems Nature 416 2002 194-199
48. Toshchakov V. Jones B.W. Perera P.Y. Thomas K. Cody M.J. Zhang S. Williams B.R. Major J. Hamilton T.A. Fenton M.J. Vogel S.N. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages Nat. Immunol. 3 2002 392-398
49. Doyle S. Vaidya S. O'Connell R. Dadgostar H. Dempsey P. Wu T. Rao G. Sun R. Haberland M. Modlin R. Cheng G.IRF3 mediates a TLR3/TLR4-specific antiviral gene program Immunity 17 2002 251-263
50. Cvetkovic R.S. Keating G. Anakinra Biodrugs 16 2002 313-314
51. Doyle S.E. O'Connell R. Vaidya S.A. Chow E.K. Yee K. Cheng G. Toll-like receptor 3 mediates a more potent antiviral response than toll-like receptor 4 J. Immunol. 170 2003 3565-3571
52. Bin LH, Xu LG, Shu HB: TIRP: a novel TIR domain-containing adapter protein involved in Toll/interleukin-1 receptor signaling. J Biol Chem 2003, in press.